MedTrace Logo

Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older

NCT07421037 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-19

No results posted yet for this study

Summary

The objective of this study was to evaluate the safety of quadrivalent subunit influenza vaccine (adjuvant) in people aged 65 years and older.

Conditions

Interventions

BIOLOGICAL

Quadrivalent Subunit Influenza Vaccine (Adjuvant)

A single 0.25 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0.

BIOLOGICAL

Quadrivalent Subunit Influenza Vaccine (Adjuvant)

A single 0.5 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0.

BIOLOGICAL

MF59

A single 0.5 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0

BIOLOGICAL

0.9% sodium chloride injection (normal saline)

A single 0.5 mL dose is administered intramuscularly into the deltoid muscle of the upper arm on Day 0.

Sponsors & Collaborators

  • Yither Biotech Co., Ltd

    collaborator UNKNOWN

  • Ab&B Bio-tech Co., Ltd.JS

    lead OTHER

Principal Investigators

  • Yeqing Tong, Doctor · Hubei Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-13
Primary Completion
2026-12-13
Completion
2026-12-13

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07421037 on ClinicalTrials.gov